Search

Showing total 2,432 results

Search Constraints

Start Over You searched for: Journal nature medicine Remove constraint Journal: nature medicine Database Springer Nature Journals Remove constraint Database: Springer Nature Journals
2,432 results

Search Results

1. Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington’s disease decades before clinical motor diagnosis

2. Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial

4. Intracerebroventricular anaerobic dopamine in Parkinson’s disease with l-dopa-related complications: a phase 1/2 randomized-controlled trial

5. Multi-omics-based mapping of decidualization resistance in patients with a history of severe preeclampsia

8. Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB–D melanoma: a phase 1/2 trial

9. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial

11. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1/2a trial

12. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial

13. Spatial multiomic landscape of the human placenta at molecular resolution

14. Deep learning versus manual morphology-based embryo selection in IVF: a randomized, double-blind noninferiority trial

15. Role of anticoagulation therapy in modifying stroke risk associated with new-onset atrial fibrillation after non-cardiac surgery

17. Molecular classification to refine surgical and radiotherapeutic decision-making in meningioma

19. An open-source framework for end-to-end analysis of electronic health record data

20. Increased frequency of repeat expansion mutations across different populations

21. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial

22. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+/HER2− breast cancer: a randomized phase 3 trial

23. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies

25. Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

26. Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma

27. In vivo base editing extends lifespan of a humanized mouse model of prion disease

28. Lifetime risk and projected burden of dementia

30. Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial

32. Medical large language models are vulnerable to data-poisoning attacks

33. The gut–brain axis underlying hepatic encephalopathy in liver cirrhosis

34. Transplantation of a genetically modified porcine heart into a live human

35. Toward expert-level medical question answering with large language models

36. High-efficiency base editing in the retina in primates and human tissues

37. A generalist medical language model for disease diagnosis assistance

39. Single-dose suraxavir marboxil for acute uncomplicated influenza in adults and adolescents: a multicenter, randomized, double-blind, placebo-controlled phase 3 trial

40. Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial

42. Effects of early, late and self-selected time-restricted eating on visceral adipose tissue and cardiometabolic health in participants with overweight or obesity: a randomized controlled trial

43. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial

45. Glecirasib in KRASG12C-mutated nonsmall-cell lung cancer: a phase 2b trial

46. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data

48. Sustained virologic suppression of multidrug-resistant HIV in an individual treated with anti-CD4 domain 1 antibody and lenacapavir

49. Clinicogenomic landscape of pancreatic adenocarcinoma identifies KRAS mutant dosage as prognostic of overall survival